Intensified process formats promise improved cost efficiency in biotherapeutics production by lowering cost of goods and increasing plant flexibility. CHO clones from traditional cell line development differ in responsiveness to process intensification and sometimes fail altogether. Therefore, tailored and time-efficient approaches are key to selecting suitable clones and developing associated USP processes.

In this clip from the ESACT Meeting 2019, Dirk Müller talks about Sartorius’ end-to-end intensified toolbox comprising of cell line, media and process development tools for getting to clinic quickly.